UMRX vs. GPCR, SYRE, AUPH, INVA, SNDX, PCRX, SPRY, ETNB, NRIX, and GERN
Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Structure Therapeutics (GPCR), Spyre Therapeutics (SYRE), Aurinia Pharmaceuticals (AUPH), Innoviva (INVA), Syndax Pharmaceuticals (SNDX), Pacira BioSciences (PCRX), ARS Pharmaceuticals (SPRY), 89bio (ETNB), Nurix Therapeutics (NRIX), and Geron (GERN). These companies are all part of the "medical" sector.
Cogent Biosciences vs.
Cogent Biosciences (NASDAQ:UMRX) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking.
Structure Therapeutics has a consensus price target of $81.29, suggesting a potential upside of 279.49%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Cogent Biosciences.
In the previous week, Structure Therapeutics had 8 more articles in the media than Cogent Biosciences. MarketBeat recorded 10 mentions for Structure Therapeutics and 2 mentions for Cogent Biosciences. Structure Therapeutics' average media sentiment score of 0.78 beat Cogent Biosciences' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media.
Cogent Biosciences has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.
Structure Therapeutics has a net margin of 0.00% compared to Cogent Biosciences' net margin of -96.84%. Structure Therapeutics' return on equity of -16.37% beat Cogent Biosciences' return on equity.
Cogent Biosciences has a beta of 3.93, meaning that its share price is 293% more volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -2.35, meaning that its share price is 335% less volatile than the S&P 500.
Cogent Biosciences received 155 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 88.57% of users gave Structure Therapeutics an outperform vote while only 68.38% of users gave Cogent Biosciences an outperform vote.
26.4% of Cogent Biosciences shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 31.5% of Cogent Biosciences shares are held by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Structure Therapeutics beats Cogent Biosciences on 11 of the 17 factors compared between the two stocks.
Get Cogent Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cogent Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:UMRX) was last updated on 3/12/2025 by MarketBeat.com Staff
